JP2007523640A - 免疫応答を誘導または調節する方法 - Google Patents

免疫応答を誘導または調節する方法 Download PDF

Info

Publication number
JP2007523640A
JP2007523640A JP2006550132A JP2006550132A JP2007523640A JP 2007523640 A JP2007523640 A JP 2007523640A JP 2006550132 A JP2006550132 A JP 2006550132A JP 2006550132 A JP2006550132 A JP 2006550132A JP 2007523640 A JP2007523640 A JP 2007523640A
Authority
JP
Japan
Prior art keywords
axotrophin
polynucleotide
polypeptide
derived
encoded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006550132A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007523640A5 (https=
Inventor
スーザン・マリー・メトカルフェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2007523640A publication Critical patent/JP2007523640A/ja
Publication of JP2007523640A5 publication Critical patent/JP2007523640A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2006550132A 2004-01-29 2005-01-31 免疫応答を誘導または調節する方法 Withdrawn JP2007523640A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0402051.7A GB0402051D0 (en) 2004-01-29 2004-01-29 Fate determination in immunity
PCT/EP2005/000934 WO2005074973A2 (en) 2004-01-29 2005-01-31 Method of inducing or modulating immune response

Publications (2)

Publication Number Publication Date
JP2007523640A true JP2007523640A (ja) 2007-08-23
JP2007523640A5 JP2007523640A5 (https=) 2008-03-21

Family

ID=31971742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006550132A Withdrawn JP2007523640A (ja) 2004-01-29 2005-01-31 免疫応答を誘導または調節する方法

Country Status (10)

Country Link
US (2) US20070286807A1 (https=)
EP (1) EP1713495A2 (https=)
JP (1) JP2007523640A (https=)
KR (1) KR20070007291A (https=)
CN (1) CN1929855A (https=)
AU (1) AU2005210105A1 (https=)
CA (1) CA2560055A1 (https=)
GB (1) GB0402051D0 (https=)
WO (1) WO2005074973A2 (https=)
ZA (1) ZA200606331B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402051D0 (en) * 2004-01-29 2004-03-03 Metcalfe Su Fate determination in immunity
ES2367012T3 (es) * 2006-02-28 2011-10-27 Charite-Universitätsmedizin Berlin Detección y control de calidad de linfocitos t reguladores a través del análisis de metilación del adn del gen foxp3.
GB0614536D0 (en) * 2006-07-21 2006-08-30 Metcalfe Susan M Methods of controlling cellular response to LIF
GB0721081D0 (en) * 2007-10-26 2007-12-05 Metcalfe Susan M Immuno-modulatory composition
WO2011015379A1 (en) * 2009-08-05 2011-02-10 Nexigen Gbmh Human hcv-interacting proteins and methods of use
EP2887954B1 (en) 2012-08-23 2020-05-06 Susan Marie Metcalfe Neurotherapeutic nanoparticle compositions
US11779683B2 (en) * 2019-04-08 2023-10-10 Loubert S. Suddaby Extended release immunomodulatory implant to facilitate bone morphogenesis
US11369473B2 (en) 2019-04-08 2022-06-28 Loubert S. Suddaby Extended release immunomodulatory implant to facilitate bone morphogenesis
CN112843222B (zh) * 2021-01-21 2023-01-31 暨南大学 Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
US20030215849A1 (en) * 2002-03-01 2003-11-20 Marcia Belvin PDPK1s as modifiers of the p53 pathway and methods of use
GB0402051D0 (en) * 2004-01-29 2004-03-03 Metcalfe Su Fate determination in immunity

Also Published As

Publication number Publication date
WO2005074973A3 (en) 2005-12-08
US20070286807A1 (en) 2007-12-13
GB0402051D0 (en) 2004-03-03
US20080125390A1 (en) 2008-05-29
KR20070007291A (ko) 2007-01-15
WO2005074973A9 (en) 2006-10-26
AU2005210105A1 (en) 2005-08-18
WO2005074973A2 (en) 2005-08-18
EP1713495A2 (en) 2006-10-25
ZA200606331B (en) 2007-12-27
CN1929855A (zh) 2007-03-14
CA2560055A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
Li et al. Systemic lupus erythematosus favors the generation of IL-17 producing double negative T cells
Stratton et al. Macrophages regulate Schwann cell maturation after nerve injury
JP6259012B2 (ja) 脱毛症の治療方法
JP6758259B2 (ja) Ｔ細胞調節方法
Aricha et al. Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis
Fueyo-González et al. Interferon-β acts directly on T cells to prolong allograft survival by enhancing regulatory T cell induction through Foxp3 acetylation
Tai et al. TLR9 deficiency promotes CD73 expression in T cells and diabetes protection in nonobese diabetic mice
US20080125390A1 (en) Methods for Modulating Immune and Inflammatory Responses
JP2007521019A (ja) 臓器再生方法
Yuan et al. Conditional reprogramming culture conditions facilitate growth of lower-grade glioma models
Li et al. Induction of immunological tolerance to myelinogenic glial-restricted progenitor allografts
Christensen et al. Fulminant lymphocytic choriomeningitis virus-induced inflammation of the CNS involves a cytokine-chemokine-cytokine-chemokine cascade
KR20140137444A (ko) 인간 림프 기관-유래 억제성 기질 세포의 분리 및 용도
KR20150016589A (ko) 염증-부여 폴리펩타이드 및 이의 용도
US20210000921A1 (en) Methods and compositions for modulating thymic function
Ko et al. Transplantation of autoimmune regulator‐encoding bone marrow cells delays the onset of experimental autoimmune encephalomyelitis
Siatskas et al. Thymic gene transfer of myelin oligodendrocyte glycoprotein ameliorates the onset but not the progression of autoimmune demyelination
Xiong et al. The experimental research of pregnancy immune tolerance induced by FTY720 via blocking S1P signal transduction pathway
Whitesell Characterizing Transient Periods of Immune Regulation Within Pancreatic Islets
Fazazi et al. Myelin-reactive B cells exacerbate the severity of CD4+ T cell-driven CNS autoimmunity in an IL-23-dependent manner
Tassey et al. GP130 Y814 SIGNALING IS REQUIRED FOR THE DYNAMIN-MEDIATED ENDOCYTOSIS, MAPK/P38 ACTIVATION AND PERSISTENCE OF CHRONIC SYSTEMIC INFLAMMATION INDUCED BY HIGH FAT DIET
WO2024200749A1 (en) Treatment of spinal injury
Burn Regulation Of Selection And Central Tolerance By The N-Terminal Region Of Rag1
Katayama et al. PHENOTYPE AND FUNCTIONAL IDENTITY OF GM-CSF INDEPENDENT DENDRITIC CELLS GENERATED BY LONG-TERM PROPAGATION OF DC PROGENITOR CELLS IN BONE MARROW CELLS AND SKIN LANGERHANS CELLS
Meyer et al. NK Cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080527

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080527

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090728